Cancer Research UK, however, was able to randomize 272 patients with potentially resectable liver metastases into either periOP FOLFOX alone as the standard treatment or FOLFOX plus the EGFR inhibitor cetuximab as the experimental arm with PFS comparison as the primary endpoint. This evidence concerns the gene EGFR and cancer.